Author:
Lin Yu-Hsuan,Hsiao Jenn-Ren,Wu Yuan-Hua,Chang Jeffrey S.,Ou Chun-Yen,Lee Wei-Ting,Huang Cheng-Chih,Chang Chan-Chi,Lai Yu-Hsuan,Tsai Sen-Tien,Hsueh Wei-Ting,Yen Chia-Jui,Lin Chen-Lin,Chen Yu-Shan,Jiang Shih-Sheng,Su Yu-Chu,Wu Shang-Yin
Abstract
Abstract
Background
To cure advanced hypopharyngeal squamous cell carcinoma (HPSCC), primary operation followed by adjuvant (chemo-)radiotherapy (OP-CRT) or definitive chemoradiation (CCRT) are the two primary options. This study aimed to compare the failure patterns and long-term survival outcomes of HPSCC patients treated with these two strategies.
Patients and Methods
From 2007 to 2015, 198 pathologically confirmed HPSCC patients receiving either OP-CRT or CCRT were retrospectively reviewed. Failure patterns and survival outcomes stratified by the 7th American Joint Committee on Cancer staging system and treatment modalities were compared.
Results
One hundred and eighty-nine patients (95.4%) were stage III/IV and 62 patients (31.3%) received OP-CRT. Median follow-up duration was 4.9 years. Compared with CCRT, OP-CRT provided better 3-year local relapse-free survival for T3 (93 vs 48%, p < 0.0001), T4a (88 vs 37%, p = 0.0005) and better 3-year regional relapse-free survival for N2b+2c (93 vs 60%, p < 0.0001). Of note, for stage IVA subjects, OP-CRT provided better 3-year loco-regional relapse-free survival (85 vs 37%, p < 0.0001), marginal poor 3-year distant metastasis-free survival (62 vs 79%, p = 0.06), but comparable 3-year OS (52 vs 44%, p = 0.37) and 5-year OS (44 vs 31%, p = 0.15) compared with CCRT.
Conclusions
For patients with advanced HPSCC, although OP-CRT and CCRT provided similar overall survival, failure patterns were distinct. OP-CRT provided better loco-regional control but was more likely to encounter distant metastases than CCRT. The detailed analysis of failure patterns will pave the way to improve this devastating disease.
Funder
Ministry of Science and Technology
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. 2020. https://gco.iarc.fr/today. Accessed 10 May 2022.
2. Kwon DI, Miles BA. Education committee of the american head and neck society (AHNS). hypopharyngeal carcinoma: Do you know your guidelines? Head Neck. 2019;41(3):569–76.
3. Newman JR, Connolly TM, Illing EA, Kilgore ML, Locher JL, Carroll WR. Survival trends in hypopharyngeal cancer: a population-based review. Laryngoscope. 2015;125(3):624–9.
4. Petersen JF, Timmermans AJ, van Dijk BAC, et al. Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands. Eur Arch Otorhinolaryngol. 2018;275(1):181–9.
5. Habib A. Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments. J Laryngol Otol. 2018;132(5):385–400.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献